Lifetime risk for development of skin cancer in the U.S. population: Current estimate is now 1 in 5
DOI 10.1016/S0190-9622(96)90139-5
Rigel DS, Friedman RJ, Kopf AW. Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. J Am Acad Dermatol. 1996;35:1012-1013. (Pubitemid 26422139)
Variation in care for nonmelanoma skin cancer in a private practice and a veterans affairs clinic
Chren MM, Sahay AP, Sands LP, Maddock L, Lindquist K, Bertenthal D, Bacchetti P. Variation in care for nonmelanoma skin cancer in a private practice and veterans affairs clinic. Med Care. 2004;42:1019-1026. (Pubitemid 39530798)
(2004)Medical Care, vol.42, Issue.10, pp. 1019-1026
5% Imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma
Torres A, Niemeyer A, Berkes B, et al. 5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. Derm Surg. 2004;30:1462-1469. (Pubitemid 40053555)
15 years' experience with treatment of basal cell carcinomas of the skin with curettage
Reymann F. 15 years' experience with treatment of basal cell carcinomas of the skin with curettage. Acta Derm Venereol Suppl (Stockh). 1985;120:56-59. (Pubitemid 16186393)
Combined curettage and excision: A treatment method for primary basal cell carcinoma
Johnson T, Tromovitch T, Swanson N. Combined curettage and excision: a treatment method for primary basal cell carcinoma. J Am Acad Dermatol. 1991;24:613-617.
Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids
DOI 10.1159/000102036
Malhotra AK, Gupta S, Khaitan BK, Sharma VK. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology. 2007;215:63-65. (Pubitemid 46976016)